Archive Course Catalog


Browse archived online courses and resources.

2020 Courses
Collapse Toxicity Management

Published January 16, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

 

This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Morgan Gwynn, PharmD, BCOP, CPP
Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
University of North Carolina Medical Center
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
  • Describe best practices for managing common side effects seen in cancer immunotherapy treatment

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


 

Continuing Education Information

 

Credit Available: 1/16/20-1/16/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

sitc_log_color.png PIM_logo.png

The 2019-2020 Advances in Cancer ImmunotherapyTM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME-MOC_badge.jpg
 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1068-H01-P)

Type of Activity: Application


Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose


Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 


If you wish to receive acknowledgment for completing this activity, please follow the steps below:

  1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
  2. Under Pending Credit, click Request Credit for Toxicity Management.
  3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
  4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
  5. Click Process Credit.
  6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

 

 

Original Course Date: January 16, 2020

Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Toxicity Management
    2019 Courses
    2018 Courses
    Collapse Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens

    Access Course

     

    Experts discuss the latest research in the use of cancer immunotherapies.

     

    This activity is intended for oncologists, pathologists, dermatologists, and other healthcare professionals who manage patients with cancer.

     

    The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 19, 2018- Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens
    Collapse Cases in mRCC: Steps to Optimizing Care

    Access Course

    Cases in mRCC: Steps to Optimize CareDr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).

     

    This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Dec. 19, 2018 -  Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACPE: 1 hour CEU
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Cases in mRCC: Steps to Optimizing Care
    Collapse Advancing the Care of Patients with SCLC: Emerging Treatment Options

    Access Course

     

    Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: Dec. 18, 2018- Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ABIM: 0.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Advancing the Care of Patients with SCLC: Emerging Treatment Options
    Collapse Case Studies in Clinical Decision Making in mCRC

    Access Course

     

    The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).

     

    The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 18, 2018 - Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Case Studies in Clinical Decision Making in mCRC
    Collapse Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?

    Access Course

    This article is for people who want to understand how biomarkers may affect their cancer treatment choices. It's also for their care partners, and others who want to learn more about the topic. The goal is to help you know what to discuss with your healthcare team about testing for biomarkers and what the results mean for your treatment.

     

     

     

     

     

     

     

    You'll explore:

    • What adjuvant therapy in melanoma is
    • Who adjuvant therapy is recommended for
    • The potential benefits of adjuvant therapy
    • About side effects of adjuvant therapy
    • Questions to ask your provider about adjuvant therapy

     

    Available beginning: Dec. 18, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018
    MORE INFOMORE INFO Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?
    Collapse Practice Your Skills: Managing Patients with Advanced NSCLC

    Access Course

     

    Practice Your Skills: Managing Patients With Advanced NSCLCApply best practices to assess, treat, and educate patients with advanced NSCLC.

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

    The goal of this activity is to build physician confidence in identifying and ordering appropriate evidence-based treatment regimens and providing patient education.

     

     

     

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: Dec. 13, 2018- Dec. 13, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 13, 2018

    Approved Credit:
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Practice Your Skills: Managing Patients with Advanced NSCLC
    Collapse Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for  oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 9, 2018- Nov. 9, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 09, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?
    Collapse Introduction to Immunology – <i>Second Edition</i>

     

    Access the updated course, Introduction to Immunology – Third Edition

    Introduction to Immunology – Third Edition is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for Introduction to Immunology – Second Edition is only available through October 9, 2019.

     

    Course Description

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    intro_to_immunology_second_edition_screenshot_2.png

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     


    SITC Resources

    Due to the rapidly-evolving field of cancer immunotherapy, some of the content in this course may be out of date. For current information from SITC on cancer immunotherapy, please reference the following resources:

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: September 28, 2018- October 9, 2019

     

    Estimated time to complete activity: 1 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-18-449-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees at Nektar Therapeutics

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period September 28, 2018 through October 9, 2019 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Introduction to Immunology – Second Edition.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete the posttest with a passing score of 75% or better and the activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: September 28, 2018

    Approved Credit:
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Introduction to Immunology – <i>Second Edition</i>
    Collapse Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

    Access Course

     

    902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.

     

    This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 27, 2018- Sep. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 27, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer
    Collapse The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

    Access Course

     

    902337.jpg?interpolation=lanczos-none&resize=300:*Learn about current and emerging immunotherapy options and how to monitor for and manage immune-related adverse events.


    This activity is intended for nurses and nurse practitioners.

     

    The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 26, 2018- Sep. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 1 hour CEU

  • MORE INFOMORE INFO The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer
    Collapse Novel Concepts in the Management of RCC

    Access Course

     

    900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
     

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 19, 2018- Sep. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 19, 2018
    MORE INFOMORE INFO Novel Concepts in the Management of RCC
    Collapse SITC 2017 Microlearning: Clinical Trials - New Agents Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


    The Clinical Trials - New Agents series contains four modules. 

     

     

    Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies

    Peter Ellmark, PhD - Alligator Bioscience


    Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents

    James L. Gulley, MD, PhD, FACP - National Cancer Institute


    Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors

    Glen J. Weiss, MD - Western Regional Medical Center Inc.


    Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

    Jason Williams, BS - University of Chicago

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - New Agents Series
    Collapse SITC 2017 Microlearning: Toxicities Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Toxicities Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


    The Toxicities series contains three modules.

     

     

    Module 1: Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis

    Jennifer Wu, PhD - Northwestern University


    Module 2: Pharmacological Management of irAEs

    Nathan Dahl, PharmD, R.Ph, BCOP - Clovis Oncology


    Module 3: Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool

    Krista Marcello, BA - Clinical Care Options, LLC

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Toxicities Series
    Collapse SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
     

    The Clinical Trials - Novel Combinations series has three modules.

     

     

    Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab

    Jose Saro, MD - Roche Innovation Center Zurich


    Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors

    Zev Wainberg, MD - UCLA School of Medicine


    Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)

    Douglas McNeel, MD, PhD - University of Wisconsin

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series
    Collapse SITC 2017 Microlearning: Additional Topics Series

    Khaaliq_Thomas_SITC_2017_HS-8.jpgThe SITC 2017 Microlearning: Additional Topics Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


    The SITC 2017 Microlearning: Additional Topics series contains three modules.

     

     

    Module 1: Genetically Modified T Cells for Solid Tumors

    Stephen Gottschalk, MD - St. Jude Children's Research Hospital


    Module 2: Improvement in Epitope Discovery

    Catherine J. Wu, MD - Dana-Farber Cancer Institute


    Module 3: Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors

    Vinod Balachandran, MD - Memorial Sloan Kettering Cancer Center

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Additional Topics Series
    Collapse SITC 2017 Microlearning: Acquired Resistance Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Acquired Resistance Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


    The Acquired Resistance Series contains three modules. 

     

     

    Module 1: Acquired Resistance Checkpoint Inhibitors in Lung Cancer

    Katerina Politi, PhD - Yale School of Medicine


    Module 2: Acquired Resistance to PD-1 Blockade in Melanoma

    Antoni Ribas, MD, PhD - University of California, Los Angeles


    Module 3: Acquired Resistance in Melanoma

    Annette Paschen, MD - University Hospital Essen

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Acquired Resistance Series
    Collapse Introduction to Cancer Immunotherapy and the Immune System

    Access the updated patient course, 2019 Patient Course: Understanding Cancer Immunotherapy – Fifth Edition

     

    This activity is based on the Patient Resource Guide, Understanding Cancer Immunotherapy 4th Edition (published in December 2017), designed for newly diagnosed and restaged cancer patients and their caregivers. This interactive activity takes a closer look at how the immune system works to fight against cancer, cancer immunotherapy treatment types and clinical trials.

    d615c873-290c-4553-bd5d-bcb549ff6cb7.jpg

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     

    Available beginning: May 22, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    This online patient education activity was produced with generous support from:

    35d50fdb-789b-42f6-8759-5ae752b880bc.jpg  
                      
                       

     

     

     

     

    Original Course Date: May 22, 2018
    MORE INFOMORE INFO Introduction to Cancer Immunotherapy and the Immune System
    Collapse Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

    Access Course

     

    892102.jpg?interpolation=lanczos-none&resize=300:*Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
     

    The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 09, 2018 - Mar. 09, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 09, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC
    Collapse Checkpoint Inhibitors: Managing Immune-Mediated Side Effects

    Access Course

     

    890963.jpg?interpolation=lanczos-none&resize=300:*Follow the cases of 2 patients who developed immune-related adverse events following treatment with immune checkpoint blockade.

     

    This activity is intended for oncologists, emergency medicine physicians, pulmonologists, and nurses.

     

    The goal of this activity is to review strategies for identifying and managing adverse events associated with treatment with immune checkpoint blockade.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 28, 2018 - Feb. 28, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 28, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Checkpoint Inhibitors: Managing Immune-Mediated Side Effects
    Collapse The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice

    Access Course

     

    890347.jpg?interpolation=lanczos-none&resize=300:*Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.


    This activity is intended for hematology/oncology specialists and pharmacists.
     

    The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 27, 2018 - Feb. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 27, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ACPE: 0.50 hours CEU
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice
    Collapse Treating Your Head and Neck Cancer: You

    Access Course

     

    889824-img1.pngThis article is for people who have advanced head and neck cancer and want to learn about working with their care team to share information about treatment and side effects and get support.

     

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Feb. 8, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 08, 2018
    MORE INFOMORE INFO Treating Your Head and Neck Cancer: You
    Collapse From Adjuvant to Metastatic in Melanoma: What Should You Know?

    Access Course

     

    From Adjuvant to Metastatic in Melanoma: What Should You Know?Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

     

    The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 24, 2018 - Dec. 24, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 17, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.50 hours CEU

  • MORE INFOMORE INFO From Adjuvant to Metastatic in Melanoma: What Should You Know?
    2017 Courses
    2016 Courses
    Collapse Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer

    Access Course

     

    1a2ba882-5629-4b61-b437-e21681e56155.jpgExperts discuss treatment strategies for one patient with recurrent HNSCC and one with locally advanced HNSCC.

    This activity is intended for oncologists, pathologists, radiologists, surgeons, and other healthcare professionals who manage patients with head and neck cancer.
     

    The goal of this activity is to discuss the emergence of immunotherapy in head and neck cancer along with treatment approaches with both curative and noncurative disease and clinical trials.

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Dec. 20, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 20, 2016
    MORE INFOMORE INFO Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer
    Collapse Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy

    Access Course

     

    dfaefd9d-8055-439e-8817-610fae557ffb.jpgWatch as an oncologist, pharmacist, and nurse discuss challenges and best practices for working in a team environment.

     


    This activity is intended for hematology and oncology specialists, nurses, advanced practice nurses and pharmacists.The goal of this activity is to identify interprofessional barriers and outline care team plans to achieve optimal outcomes for patients with non-small cell lung cancer (NSCLC).

     

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy
    Collapse Kidney Cancer Treatments: Is One Option Better Than Another for Me?

    Access Course

     

    888494-fig1.pngThis article is for people who’ve had treatment for kidney cancer that has now spread, called metastatic renal cell carcinoma (mRCC). It’s also for their care partners and others who want to learn more about the next treatment choices. The goal is to learn about all your treatment options so you can better decide with your care team what’s right for you.

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Kidney Cancer Treatments: Is One Option Better Than Another for Me?
    Collapse Clinical Challenges in Melanoma: Progressive Disease

    Access Course

     

    Clinical Challenges in Melanoma: Progressive DiseaseImaging scans suggest this patient's melanoma has progressed, but has it? Watch this case to see how it develops.

    This activity is intended for oncologists, dermatologists and pathologists.

    The goal of this activity is to review the treatment options and patterns of progression in patients being treated for metastatic melanoma.

     

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Dec. 7, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 07, 2016
    MORE INFOMORE INFO Clinical Challenges in Melanoma: Progressive Disease
    Collapse New Frontiers in Decision Making: Adverse Events with Immunotherapy in NSCLC

    Access Course

     

    New Frontiers in Decision Making: Adverse Events With Immunotherapy in NSCLC

    Use a patient case to learn about managing adverse events with immunotherapy in patients with NSCLC.


    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists. 
     

    The goal of this activity is to address how to start integrating immune checkpoint inhibitors into lung cancer treatment.

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 6, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Adverse Events with Immunotherapy in NSCLC
    Collapse New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC

    Access Course

     

    medscapeact142016.JPGFollow a patient with advanced adenocarcinoma to learn about the use and management of immune checkpoint inhibitors.

    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.


    The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.

     

     

    Approximate Time to Complete: 20 minutes

     

    Credit Available: Dec. 6, 2016- Dec. 6, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC
    Collapse Advancing the Care in Thoracic Cancer: Emerging Treatment Options

    Access Course

     

    9fcc4845-b7a8-4518-b7c8-171470014791.jpgRead three articles that review immunotherapy treatment options in mesothelioma, small cell lung cancer, and non-small cell lung cancer.


    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

    The goal of this activity is to increase awareness of immunotherapy as a treatment option for extensive disease in thoracic cancers.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Nov. 30, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 30, 2016
    MORE INFOMORE INFO Advancing the Care in Thoracic Cancer: Emerging Treatment Options
    Collapse Optimizing Outcomes in Metatastic Melanoma: A Case Challenge

    Access Course

     

    Medscape_act_21_2017.jpgReview appropriate treatment regimens for patients with metastatic melanoma.


    This educational activity is intended for clinicians practicing in the areas of hematology-oncology, dermatology, pathology and lab medicine. 


    The goal of this activity is to build healthcare professionals' confidence in strategies for the individualized treatment of the patient with malignant melanoma and to ensure that updated guidelines and other emerging best practices are applied across a variety of clinical presentations.

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Nov. 22, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 22, 2016
    MORE INFOMORE INFO Optimizing Outcomes in Metatastic Melanoma: A Case Challenge
    Collapse Essential Concepts in Harnessing the Immune System in Head and Neck Cancer

    Access Course

     

    medscapeact122016.jpgDr. Tanguy Seiwert explores the emerging role for immunotherapy in head and neck cancer. 


    This activity is intended for oncologists, surgeons, and pathologists. 

    The goal of this activity is to discuss advances in the understanding of the role of the immune system in the head and neck cancer and strategies for using the immune system to treat head and neck cancer.

     

     

    Approximate Time to Complete: 40 minutes

     

    Course Available Beginning: Nov. 15, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 15, 2016
    MORE INFOMORE INFO Essential Concepts in Harnessing the Immune System in Head and Neck Cancer
    Collapse Is Immunotherapy Right for My Lung Cancer?

    Access Course

     

    medscape-_LungPatient2.jpgThis activity is for people with non-small cell lung cancer who want to learn more about why, how, and when their care team may consider using immunotherapy as part of their treatment.

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Nov. 8, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 08, 2016
    MORE INFOMORE INFO Is Immunotherapy Right for My Lung Cancer?
    Collapse Immunotherapy Side Effects: Talking with Your Melanoma Care Team

    Access Course

     

    patient_medscape-melanoma_side_effects.jpgThis article is for people who are taking checkpoint inhibitor medicines for metastatic melanoma, their care partners, and others who want to learn about treatment side effects.

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Nov. 8, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 08, 2016
    MORE INFOMORE INFO Immunotherapy Side Effects: Talking with Your Melanoma Care Team
    Collapse New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC

    Access Course

     

    53fbb258-d3ff-479d-922a-3d8130eabc61.jpgFollow a patient with advanced squamous cell NSCLC to learn about the use and management of immune checkpoint inhibitors.


    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.


    The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Oct. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 21, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC
    Collapse Clinical Challenges in Melanoma: Frontline

    Access Course

     

    617d9a96-bcfa-4ed5-8d8a-325b95a8c380.jpgA patient undergoing treatment for metastatic melanoma experiences some unusual symptoms. Watch this case to figure out what is going on.

    This activity is intended for oncologists, dermatologists, and pathologists.

    The goal of this activity is to review the treatment options and risks for immune-related adverse effects in patients being treated for metastatic melanoma.

     

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Oct. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 21, 2016
    MORE INFOMORE INFO Clinical Challenges in Melanoma: Frontline
    Collapse Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy?

    Access Course

     

    patient_medscape-_immunotherapy_the_same_as_chemo.jpgThis activity is for people with non-small cell lung cancer (NSCLC) who want to learn more about how immunotherapy differs from chemotherapy.

     

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 20, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 20, 2016
    MORE INFOMORE INFO Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy?
    Collapse What Treatment is Right for My Metatastic Melanoma

    Access Course

     

    patient_medscape-_melanoma.jpg

     

    This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy. This activity is intended for oncologists, dermatologists, pathologists, and healthcare practitioners who care for patients with metastatic melanoma. The goal of this activity is to educate clinicians in the practical application of recently approved systemic.

     

    Upon completion of this activity, participants will be able to:

    Select opitmal therapy for patients with metastatic melanoma that harbors v600 BRAF mutations and for patients with wild-type BRAF. Explain the role of immunotherapy in patients with V600 BRAF mutation-positive metastatic melanoma. Outline a sequential treatment strategy for patients with V600 BRAF mutation-positive metastatic melanoma. Describe how to manage side effects and assess response to immunotherapy and targeted therapy in patients being treated for metastatic melanoma. 

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 19, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 19, 2016
    MORE INFOMORE INFO What Treatment is Right for My Metatastic Melanoma
    Collapse Patient-Centered Management in Metastatic Renal Cell Carcinoma

    Access Course

     

    e3b71881-082a-4b52-b05c-867a9c5798ce.jpgExplore some of the main issues in the treatment of advanced RCC through two cases. 

     

    This activity is intended for oncologists, nephrologists, urologists, and other healthcare professionals who treat patients with advanced RCC.

     

    The goal of this activity is to examine the options for second-line treatment of mRCC as well as strategies for working with the patient.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Sep. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 21, 2016
    MORE INFOMORE INFO Patient-Centered Management in Metastatic Renal Cell Carcinoma
    Collapse Priming T-Cells: Do We Understand the Strategies?

    Access Course

     

    0bd87a52-42d9-41ee-8176-461723604db4.jpgThree articles examine the role of T cells in the anticancer immune response and how they are being used in therapy.


    This activity is intended for hematologists and oncologists, pulmonologists and dermatologists.The goal of this activity is to explore advances being made in the harnessing of T cells for cancer immunotherapies.

     

     

    Approximate Time to Complete: 1.25 hours

     

    Credit Available: Sept. 15, 2016- Sept. 15, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 15, 2016
    MORE INFOMORE INFO Priming T-Cells: Do We Understand the Strategies?
    Collapse Pulmonologist Perspectives: The Use of Immune Checkpoint Inhibitors in Practice

    Access Course

     

    4a9408df-ed81-42bf-8167-018443e9f780.jpgLearn how treatment of NSCLC with checkpoint inhibitors will affect your clinical outlook.


    This activity is intended for pulmonologists, ID/HIV specialists, and pathologists who treat patients with lung cancer.

    The goal of this activity is to provide pulmonologists perspectives on how immune checkpoint inhibitors may alter the diagnostic algorithm in individuals with suspected lung cancer. 

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Aug. 31, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 31, 2016
    MORE INFOMORE INFO Pulmonologist Perspectives: The Use of Immune Checkpoint Inhibitors in Practice
    Collapse Spotlight on Immuno-Oncology in Melanoma

    Access Course

     

    966d4d06-8467-4d53-97ef-f5df8727a722.jpgDrs. Weber, Luke, and Gangadhar discuss the latest updates to existing immunotherapies and examine where the future may lie. 

    This activity is intended for hematologists, oncologists, dermatologists, and pathologists. 

    The goal of this activity is to review the latest advances in immunotherapy for melanoma.

     

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Aug. 31, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Original Course Date: August 31, 2016
    MORE INFOMORE INFO Spotlight on Immuno-Oncology in Melanoma
    Collapse Cancer Immunotherapy: Pathways and Mechanisms of Actions

    Access Course

     

    4f67197e-85c7-4982-9169-585f0d5cb12b.jpg

    Experts discuss the basics of the immune system as well as existing and novel targets for cancer immunotherapy.

     

    This activity is intended for hematologist/oncologists, pulmonologists, dermatologists, and other healthcare professionals who use cancer immunotherapies.

     

    The goal of this activity is to review the role of the immune system in the development of tumors and research into the use of the immune system to fight tumors.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Cancer Immunotherapy: Pathways and Mechanisms of Actions
    Collapse Hiding in Plain Sight: How Cancer Evades the Immune System

    Access Course

     

    medscapeact22016.jpgDr. Robert Ferris reviews the working of the immune system and the development of cancer. 

    This activity is intended for hematologists, oncologists, pulmonologists, dermatologist, immunologists, primary care providers, and other healthcare providers who use cancer immunotherapies.

     

    The goal of this activity is to review the latest understanding of the relationship between the immune system and the tumor microenvironment as well as new immunotherapies in the management of patients with cancer. 

     

     

    Approximate Time to Complete: 30 minutes

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Hiding in Plain Sight: How Cancer Evades the Immune System
    Collapse Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer

    Access Course

     

    medscape5_v1.jpgDrs. Weiss, Borghaei, and Patel discuss the clinical data and practical implications for using checkpoint inhibitors to treat lung cancer. 


    This activity is intended for hematology and oncology specialists, pulmonologists and pathologists.
     

    The goal of this activity is to provide insight on how recently published clinical trials on immune checkpoint inhibitors should be incorporated into practice.

     

     

    Approximate Time to Complete: 40 minutes

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer
    Collapse Changing the Paradigm of Treatment in Patients with Hodgkin Lymphoma

    Access Course

     

    b827ba58-216e-4f06-897a-9cc44942e390.jpgDr. Stephen Ansell discusses the emerging role of immunotherapy in the management of patients with Hodgkin lymphoma.


    This activity is intended for hematologists, oncologists, pathologists, and other healthcare professionals who treat patients with Hodgkins lymphoma.


    The goal of this activity is to discuss the latest understanding of the role of the immune system in the development of Hodgkin lymphoma as well as strategies for harnessing the immune 

     

    Approximate Time to Complete: 30 minutes

     

    Course Available Beginning: Aug. 14, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 14, 2016
    MORE INFOMORE INFO Changing the Paradigm of Treatment in Patients with Hodgkin Lymphoma